JP6830896B2 - 溶解ガス発生流体を有するコントラスト造影剤 - Google Patents
溶解ガス発生流体を有するコントラスト造影剤 Download PDFInfo
- Publication number
- JP6830896B2 JP6830896B2 JP2017543960A JP2017543960A JP6830896B2 JP 6830896 B2 JP6830896 B2 JP 6830896B2 JP 2017543960 A JP2017543960 A JP 2017543960A JP 2017543960 A JP2017543960 A JP 2017543960A JP 6830896 B2 JP6830896 B2 JP 6830896B2
- Authority
- JP
- Japan
- Prior art keywords
- gas
- contrast
- imaging
- fluid
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012530 fluid Substances 0.000 title claims description 190
- 239000002872 contrast media Substances 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 claims description 99
- 210000004072 lung Anatomy 0.000 claims description 70
- 238000003384 imaging method Methods 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 31
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 21
- 238000013170 computed tomography imaging Methods 0.000 claims description 17
- 238000002059 diagnostic imaging Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 102000004506 Blood Proteins Human genes 0.000 claims description 7
- 108010017384 Blood Proteins Proteins 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 238000013016 damping Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 210000002837 heart atrium Anatomy 0.000 claims 2
- 239000007789 gas Substances 0.000 description 145
- 238000002591 computed tomography Methods 0.000 description 38
- 229910052724 xenon Inorganic materials 0.000 description 32
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 32
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 125000004429 atom Chemical group 0.000 description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 239000011630 iodine Substances 0.000 description 10
- 238000002603 single-photon emission computed tomography Methods 0.000 description 10
- 229910052743 krypton Inorganic materials 0.000 description 8
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 8
- 229910018503 SF6 Inorganic materials 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 7
- 229960000909 sulfur hexafluoride Drugs 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- 239000003633 blood substitute Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940039231 contrast media Drugs 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- -1 aryl compound Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical group COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- JTYRBFORUCBNHJ-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JTYRBFORUCBNHJ-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000011358 absorbing material Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 229960001217 perflubron Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- AAWVDEWPDIOBAN-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-octadecafluorooctane hydrobromide Chemical compound Br.FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F AAWVDEWPDIOBAN-UHFFFAOYSA-N 0.000 description 1
- COQIQRBKEGPRSG-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(F)(C(F)(F)F)C(F)(F)F COQIQRBKEGPRSG-UHFFFAOYSA-N 0.000 description 1
- LANNRYWUUQMNPF-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)Br LANNRYWUUQMNPF-UHFFFAOYSA-N 0.000 description 1
- CVEIKEYTQKDDQK-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,4-nonafluorobutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)Br CVEIKEYTQKDDQK-UHFFFAOYSA-N 0.000 description 1
- VPQQZKWYZYVTMU-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br VPQQZKWYZYVTMU-UHFFFAOYSA-N 0.000 description 1
- WQELDDKOSOQCBX-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoyl bromide Chemical class FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(Br)=O WQELDDKOSOQCBX-UHFFFAOYSA-N 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002221 fluorine Chemical group 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950003332 perflubutane Drugs 0.000 description 1
- SNGREZUHAYWORS-UHFFFAOYSA-N perfluorooctanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-N 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1025—Respiratory system
- A61M2210/1039—Lungs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Theoretical Computer Science (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Description
本出願は、2015年2月20日に出願され、「Contrast Imaging Agent With Dissolved Gas」と題する米国特許仮出願第62/118946号明細書、および2015年2月20日に出願され、「A System and Method for Combined Gaseous/Liquid Imaging Agent Imaging」と題する米国特許仮出願第62/118517号明細書(これらの開示は、その全体が参照により本明細書に組み込まれる)に対する優先権を主張する。
12 本体
13 近位端部
14 高クラック圧弁
14’ 高クラック圧弁
15 遠位端部
16 気密キャップ、シリンジ
17 側壁
18 供給ライン
19 縦軸
20 バスキュラーアクセス流体経路セット、バスキュラーアクセス流体経路
21 ノズル
22 患者
23 プランジャー
25 ポート
40 供給システム
42 注入器
50 撮像システム
Claims (14)
- 肺の気胞の診断画像処置のためにある濃度の気体コントラスト剤を肺の気胞内に放出する診断用コントラスト組成物であって、
キャリア流体と、
前記キャリア流体に取り込まれた非減衰性ガス発生液体と
を含み、前記ガス発生液体が、経時的に減衰しない撮像特性を有し、ペルフルオロカーボン、臭素化ペルフルオロカーボンおよびこれらの組合せから選択され、循環系から患者の肺の気胞内へ気体のペルフルオロカーボン、臭素化ペルフルオロカーボンおよびこれらの組合せを発生させるのに十分な蒸気圧を有し、前記非減衰性ガス発生液体の撮像関連特性が、経時的に減衰しない、診断用コントラスト組成物。 - 前記ガス発生液体が、CT撮像システムにおける画像のハウンズフィールド単位測定値を高くするのに十分な吸収の増加をもたらす、十分な量のフッ素原子及び臭素原子のうち少なくとも1つを含む組成物である請求項1に記載の診断用コントラスト組成物。
- 前記ガス発生液体が、ペルフルオロカーボンである、請求項1または2に記載の診断用コントラスト組成物。
- 前記キャリア流体が、水、食塩水、1つまたは複数の血液タンパク質を含む食塩水、および溶解脂質を含む食塩水からなる群から選択される請求項1〜3のいずれか一項に記載の診断用コントラスト組成物。
- 診断用コントラストが、少なくとも1つの液体または溶解したX線コントラスト造影剤をさらに含む請求項1〜4のいずれか一項に記載の診断用コントラスト組成物。
- 容器または供給システム内の前記診断用コントラスト組成物の上昇した圧力により前記ガス発生液体の濃度が上昇する請求項1〜5のいずれか一項に記載の診断用コントラスト組成物。
- 前記容器または供給システム内の前記診断用コントラスト組成物の上昇した前記圧力が1.5atm〜30atmの範囲である請求項6に記載の診断用コントラスト組成物。
- 前記ガス発生液体の前記濃度を上昇させる、前記キャリア流体内で溶解、懸濁または乳化した少なくとも1つの濃度上昇組成物をさらに含む請求項1〜7のいずれか一項に記載の診断用コントラスト組成物。
- 前記濃度上昇組成物が第2のガス発生流体である請求項8に記載の診断用コントラスト組成物。
- 肺の気胞の診断画像処置のためにある濃度の気体コントラスト剤を肺の気胞内に放出する診断用コントラスト組成物を調製するための方法であって、
キャリア流体を容器内に供給するステップと、
非減衰性ガス発生液体をキャリア流体に溶解させるステップと
を含み、前記非減衰性ガス発生液体が、経時的に減衰しない撮像特性を有し、ペルフルオロカーボン、臭素化ペルフルオロカーボンおよびその組み合わせから選択され、循環系から患者の肺の気胞内へ気体のペルフルオロカーボン、臭素化ペルフルオロカーボンおよびその組み合わせを発生させるのに十分な蒸気圧を有し、前記非減衰性ガス発生液体の撮像関連特性が、経時的に減衰しない、診断用コントラスト組成物を調製するための方法。 - 前記ガス発生液体を前記キャリア流体に圧力1.5atm〜30atmの範囲で溶解させることによって前記ガス発生液体の濃度を上昇させるステップをさらに含む請求項10に記載の方法。
- 前記ガス発生液体が、CT撮像システムにおける画像に影響するハウンズフィールド単位測定値を与える、十分な量のフッ素原子及び臭素原子のうち少なくとも1つを含む組成物である請求項10または11に記載の方法。
- 前記ガス発生液体が、ペルフルオロカーボンである、請求項10から12のいずれか一項に記載の方法。
- 前記キャリア流体が、水、食塩水、1つまたは複数の血液タンパク質を含む食塩水、および溶解脂質を含む食塩水からなる群から選択される請求項10から13のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562118517P | 2015-02-20 | 2015-02-20 | |
US201562118946P | 2015-02-20 | 2015-02-20 | |
US62/118,946 | 2015-02-20 | ||
US62/118,517 | 2015-02-20 | ||
PCT/US2016/018707 WO2016134275A1 (en) | 2015-02-20 | 2016-02-19 | Contrast imaging agent with dissolved gas-evolving fluid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018512384A JP2018512384A (ja) | 2018-05-17 |
JP6830896B2 true JP6830896B2 (ja) | 2021-02-17 |
Family
ID=56689487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017543960A Active JP6830896B2 (ja) | 2015-02-20 | 2016-02-19 | 溶解ガス発生流体を有するコントラスト造影剤 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20180064830A1 (ja) |
EP (1) | EP3258850B1 (ja) |
JP (1) | JP6830896B2 (ja) |
WO (1) | WO2016134275A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016138449A1 (en) | 2015-02-27 | 2016-09-01 | Bayer Healthcare Llc | Quantification phantom for use with multiple imaging modalities |
JP6699339B2 (ja) * | 2016-05-13 | 2020-05-27 | コニカミノルタ株式会社 | 動態解析システム |
JP7291712B2 (ja) * | 2017-11-12 | 2023-06-15 | シーネクス メディカル インコーポレイテッド | 装着型の血液検体測定装置及び血液検体濃度を測定する方法 |
CN111449657B (zh) * | 2020-04-15 | 2021-05-18 | 中国医学科学院北京协和医院 | 图像监测系统和肺栓塞诊断系统 |
US20220000480A1 (en) * | 2020-07-02 | 2022-01-06 | Covidien Lp | Surgical stapling device |
CN112268920B (zh) * | 2020-10-13 | 2021-12-31 | 大连理工大学 | 应用mri原位测量储层温压下co2-盐水对流混合的装置及方法 |
RU2753474C1 (ru) * | 2020-12-07 | 2021-08-17 | Государственное бюджетное учреждение здравоохранения города Москвы "Научно-практический клинический центр диагностики и телемедицинских технологий Департамента здравоохранения города Москвы" (ГБУЗ "НПКЦ ДиТ ДЗМ") | Способ низкодозного сканирования органов грудной клетки, адаптированный к массе тела пациента |
CN115708693B (zh) * | 2022-10-24 | 2024-02-27 | 无忧跳动医疗科技(深圳)有限公司 | 一种全自动发泡装置及方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3975512A (en) | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
US4865836A (en) | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US5024230A (en) * | 1988-11-23 | 1991-06-18 | Picker International, Inc. | Dual flow/lambda display for xenon enhanced tomography |
US5046498A (en) * | 1991-01-16 | 1991-09-10 | Union Carbide Industrial Gases Technology Corporation | Magnetic resonance human medical and veterinary imaging method |
US5271401A (en) * | 1992-01-15 | 1993-12-21 | Praxair Technology, Inc. | Radiological imaging method |
US5383858B1 (en) | 1992-08-17 | 1996-10-29 | Medrad Inc | Front-loading medical injector and syringe for use therewith |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5357959A (en) * | 1993-04-16 | 1994-10-25 | Praxair Technology, Inc. | Altered dipole moment magnetic resonance imaging method |
US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
US5824703A (en) * | 1994-05-13 | 1998-10-20 | Synthetic Blood International, Inc. | Method of assisting normal breathing in a mammal having a lung disorder |
EP0890114A1 (en) * | 1996-03-29 | 1999-01-13 | Lawrence Berkeley National Laboratory | Enhancement of nmr and mri in the presence of hyperpolarized noble gases |
US5944694A (en) | 1996-11-12 | 1999-08-31 | Medrad, Inc. | Prefillable syringes and injectors for use therewith |
EP1075654A4 (en) | 1998-04-27 | 2003-06-04 | Gen Hospital Corp | SYSTEM AND ASSEMBLY FOR HANDLING RADIOACTIVE MATERIAL |
US6652489B2 (en) | 2000-02-07 | 2003-11-25 | Medrad, Inc. | Front-loading medical injector and syringes, syringe interfaces, syringe adapters and syringe plungers for use therewith |
JP2003526437A (ja) * | 2000-03-13 | 2003-09-09 | メディ−フィジックス・インコーポレイテッド | ガス状過分極129Xeの直接注射を使用する診断処置並びに関連するシステムおよび生成物 |
PL226184B1 (pl) | 2001-01-23 | 2017-06-30 | Aventis Pasteur | Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko |
US7553294B2 (en) | 2002-05-30 | 2009-06-30 | Medrad, Inc. | Syringe plunger sensing mechanism for a medical injector |
US7666169B2 (en) | 2003-11-25 | 2010-02-23 | Medrad, Inc. | Syringe and syringe plungers for use with medical injectors |
US20070258908A1 (en) * | 2006-04-27 | 2007-11-08 | Lanza Gregory M | Detection and imaging of target tissue |
ES2648524T3 (es) | 2009-07-24 | 2018-01-03 | Bayer Healthcare Llc | Jeringa para un sistema inyector de fluido |
CA2820557A1 (en) | 2010-11-29 | 2012-06-07 | Sanofi-Aventis Deutschland Gmbh | Auto-injector device with a medicated module |
WO2012155035A1 (en) | 2011-05-12 | 2012-11-15 | Medrad, Inc. | Fluid injection system having various systems for controlling an injection procedure |
US20140276379A1 (en) | 2013-03-15 | 2014-09-18 | Medrad, Inc. | Intelligent and configurable fluid delivery system and methods for its use |
NZ726432A (en) | 2014-04-25 | 2022-07-01 | Bayer Healthcare Llc | Syringe with rolling diaphragm |
US9199033B1 (en) | 2014-10-28 | 2015-12-01 | Bayer Healthcare Llc | Self-orienting syringe and syringe interface |
-
2016
- 2016-02-19 EP EP16753159.9A patent/EP3258850B1/en active Active
- 2016-02-19 JP JP2017543960A patent/JP6830896B2/ja active Active
- 2016-02-19 WO PCT/US2016/018707 patent/WO2016134275A1/en active Application Filing
- 2016-02-19 US US15/551,469 patent/US20180064830A1/en not_active Abandoned
-
2020
- 2020-07-28 US US16/940,601 patent/US11576985B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018512384A (ja) | 2018-05-17 |
EP3258850A1 (en) | 2017-12-27 |
EP3258850A4 (en) | 2018-10-17 |
US20200353103A1 (en) | 2020-11-12 |
US11576985B2 (en) | 2023-02-14 |
EP3258850B1 (en) | 2020-06-24 |
WO2016134275A1 (en) | 2016-08-25 |
US20180064830A1 (en) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6830896B2 (ja) | 溶解ガス発生流体を有するコントラスト造影剤 | |
Cademartiri et al. | Intravenous contrast material administration at helical 16–detector row CT coronary angiography: effect of iodine concentration on vascular attenuation | |
KR0177532B1 (ko) | 변형된 쌍극자 모멘트 자기 공명 영상화 방법 | |
JP2914468B2 (ja) | 放射線医学的イメージング法 | |
KR102210774B1 (ko) | 세미플루오로탄소 화합물을 함유하는 조영제 | |
Kao et al. | Long-residence-time nano-scale liposomal iohexol for X-ray–based blood pool imaging | |
RU2664418C2 (ru) | Контрастные среды с низкой концентрацией йода для рентгеновской визуализации и способ рентгеновской визуализации | |
JPH03500896A (ja) | 磁気共鳴画像診断装置における画像化のために、酸素‐17を組織内に導入する方法 | |
JP2011084583A (ja) | 短時間型β遮断薬を有効成分とする心拍数減少剤 | |
RU2106880C1 (ru) | Физиологически приемлемый оксигенированный водный раствор рентгеноконтрастирующего вещества и способ его получения | |
RU2016117767A (ru) | Система для управления током крови и способ получения изображений в живом организме | |
BR112012009859B1 (pt) | composição de diagnóstico | |
US20050053551A1 (en) | Use of a combination of gadolinium-based contrast media and iodinated contrast media as a contrast agent for X-ray based medical imaging procedures | |
Alpert et al. | In-vivo imaging of mitochondrial depolarization of myocardium with positron emission tomography and a proton gradient uncoupler | |
Spiliopoulos et al. | Digital Subtracted Angiography of Small Animals | |
Wietholt et al. | Comparison of CT contrast blood pool agents for in-vivo 3D angiography using microCT | |
JP2019182759A (ja) | X線用陰性造影剤 | |
WO2005030262A1 (en) | Use of a gas for the manufacture of a diagnosing agent for diagnosing coronary perfusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191028 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6830896 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |